Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: COPD

Spiriva® HandiHaler (tiotropium bromide) inhalation powder

Approval Date: Jun 2023

Note: First-Time Generic

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Daliresp® (roflumilast) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol

Approval Date: Mar 2022

Note: First-Time Generic

A first-time generic for Symbicort, this drug is indicated for the treatment of COPD and asthma.

Perforomist® (formoterol fumarate) inhalation solution

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Perforomist. For the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Brovana® (arformoterol tartrate) inhalation solution

Approval Date: Jun 2021

Note: First-Time Generic

This is the first time a generic has been approved for Brovana. For the long-term, twice daily administration in the maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Medication Name

Approval Date

Category

Description

Spiriva® HandiHaler (tiotropium bromide) inhalation powder

Jun 2023

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Note: First-Time Generic

Daliresp® (roflumilast) tablets

Sep 2022

Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

Note: First-Time Generic

Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol

Mar 2022

A first-time generic for Symbicort, this drug is indicated for the treatment of COPD and asthma.

Note: First-Time Generic

Perforomist® (formoterol fumarate) inhalation solution

Jun 2021

This is the first time a generic has been approved for Perforomist. For the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Note: First-Time Generic

Brovana® (arformoterol tartrate) inhalation solution

Jun 2021

This is the first time a generic has been approved for Brovana. For the long-term, twice daily administration in the maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Note: First-Time Generic
lockenvelopephone-handsetmagnifiermenucross-circle